Glutamate Probes in Adolescent Depression
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 14-004662
NCT ID: NCT02307617
Sponsor Protocol Number: 14-004662
About this study
The purpose of this study is to learn if measures of brain chemicals from a brain scan called Magnetic Resonance Imaging and Spectroscopy (MRI/MRS) and brain activity (known as cortical excitability and inhibition) collected by Transcranial Magnetic Stimulation (TMS) are different in adolescents with depression who are in different stages of treatment. Researchers are conducting this study to learn more about how the brain works in adolescents with depression and without depression (healthy controls). This is important because it may identify a biological marker (a measure of how bad an illness is) for depression that could one day be used to identify depressed adolescents who would benefit from certain treatments (medications for example) or to monitor how well treatments are working.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Adolescents from the ages of 13 to 21, male or female.
-
Subjects with MDD (Groups 2,3 & 4):
- Group 1: (Healthy Controls; 50 Subjects): Healthy volunteers who are 13-21 years of age with no current or lifetime mental health diagnoses and no current or lifetime psychotropic medication treatment.
-
Group 2: (50 subjects): Subjects with moderate to severe MDD who have initiated treatment with an SSRI no more than 7 days prior to the baseline visit.
- Subjects and parents in group 2 will be eligible to return in 6-8 weeks for a follow up visit that includes mood assessments and evaluations.
- Subjects who have been adherent to their clinically prescribed medication will be eligible for a second MRI/MRS scan and TMS measures within 7 days of the second visit.
-
Group 3: (50 subjects): Subjects with moderate to severe MDD that has responded to treatment with an SSRI.
• Response will be defined as a 1 (very much) or 2 (much) improved on a CGI-Improvement Scale. This is the current acceptable standard in child and adolescent psychopharmacological research.
- Group 4: (50 subjects): Subjects with moderate to severe MDD that has not responded to treatment with an SSRI as defined above with CGI scale score.
- Subject and parent or guardian (if under age 18) must be capable of providing informed consent
- Subjects must be right-handed.
- Subjects and at least 1 parent must be fluent in English. • Subjects 18 years of age or older do not require an English-speaking parent
Exclusion Criteria:
-
Exclusion Criteria For all Subjects:
-
Exclusion Criteria for Healthy Control Group only:
- Current or past mental health diagnoses in subjects or first degree relatives of subjects.
- Current or past mental health medications.
-
Exclusion Criteria for MDD Groups only:
- Primary Axis I or II disorder other than MDD.
- Unprovoked seizure history, seizure disorder, history of febrile seizures, first degree relative with epilepsy
- Taking medication(s) that lower seizure threshold
- Any significant findings on the TMS adult safety screen (TASS).
-
Exclusion Criteria for Group 2 only:
- Subject has started SSRI medication more than 7 days prior to the baseline visit.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Paul Croarkin, D.O., M.S. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available